PCVX
PCVX
NASDAQ · Biotechnology

Vaxcyte Inc

$55.91
+1.24 (+2.27%)
As of Mar 25, 9:47 PM ET ·
Financial Highlights (FY 2025)
Revenue
3.07B
Net Income
147.42M
Gross Margin
53.6%
Profit Margin
4.8%
Rev Growth
+1.9%
D/E Ratio
1.24
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 53.6% 53.6% 53.6%
Operating Margin 6.1% 5.8% 5.8%
Profit Margin 4.8% 5.0% 5.2%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 3.07B 3.02B 2.41B
Gross Profit 1.64B 1.62B 1.29B
Operating Income 186.01M 175.77M 140.58M
Net Income 147.42M 150.65M 124.53M
Gross Margin 53.6% 53.6% 53.6%
Operating Margin 6.1% 5.8% 5.8%
Profit Margin 4.8% 5.0% 5.2%
Rev Growth +1.9% +8.9% +10.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 4.24B 4.14B 4.52B
Total Equity 3.42B 3.07B 3.05B
D/E Ratio 1.24 1.35 1.48
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 264.93M 279.22M 238.21M
Free Cash Flow 132.34M 114.72M 94.55M